author-photo

A. Di Leo

Institut Jules Bordet

118

Papers

15396

Citations

Citation Trend

Filter By

Papers (82) Sort By

Journal Conference Others

Abstract P6-09-02: Effects of palbociclib on thymidine kinase-1 (TK1) in hormone receptor positive (HR+) breast cancer cell lines

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PD6-07: Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract P5-21-02: Efficacy and safety of abemaciclib in patients with liver metastases in the MONARCH 1, 2, and 3 studies

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Abstract GS6-02: The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (7)
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

2018 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (229)
Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (52)
Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (81)
Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
95PGene signatures as potential predictive markers of response to neoadjuvant chemotherapy in ER+/HER2+ breast cancer patients

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
322TiPPYTHIA: A phase II study of palbociclib plus fulvestrant for pretreated patients with ER+/HER2- metastatic breast cancer

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)